Therapy and medicine
We have developed a therapy that will be applied on the basis of a new drug. The drug is produced by means of a genetic engineering process. The process completely dispenses with animal components, making less complex production processes necessary.
The BelACT therapy is based on an enzyme mixture. The scientific basis is partly secured by patents and partly by internal processes, taking into account the requirements of GMP. The production and approval of the genetically recombinant drug takes place in Germany.
The present project study was prepared by the members of the Board of Trustees and prepared for the necessary approval processes. The various aspects concerning feasibility, proof of function and realisation have been proven and described in individual cases.
The members of the Board of Trustees have given us the certainty that the goal of a new drug is purposefully enforceable.